These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29381220)

  • 21. Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming.
    Mould DR; Upton RN; Wojciechowski J; Phan BL; Tse S; Dubinsky MC
    AAPS J; 2018 Jun; 20(4):76. PubMed ID: 29904814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
    Williet N; Paul S; Peyrin-Biroulet L; Roblin X
    Dig Dis Sci; 2016 Apr; 61(4):990-5. PubMed ID: 26669880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab therapy intensification upon loss of response: Is there an optimal trough level?
    Ungar B; Ben-Shatach Z; Ben-Haim G; Yavzori M; Picard O; Fudim E; Kopylov U; Veyrard P; Del Tedesco É; Paul S; Eliakim R; Ben-Horin S; Roblin X
    Dig Liver Dis; 2019 Aug; 51(8):1106-1111. PubMed ID: 30928420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
    AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.
    Pouillon L; Ferrante M; Van Assche G; Rutgeerts P; Noman M; Sabino J; Vande Casteele N; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1276-1283.e1. PubMed ID: 29203225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent.
    Polakovicova V; Kadleckova B; Lucenicova J; Otottova K; Kinova S; Mikus P; Zelinkova Z
    Dig Liver Dis; 2019 Aug; 51(8):1112-1116. PubMed ID: 31147215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.
    Cao Y; Dai Y; Zhang L; Wang D; Yu Q; Hu W; Wang X; Yu P; Ping Y; Sun T; Sang Y; Liu Z; Chen Y; Tao Z
    Clin Biochem; 2022 Feb; 100():35-41. PubMed ID: 34843732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.
    Dotan I; Ron Y; Yanai H; Becker S; Fishman S; Yahav L; Ben Yehoyada M; Mould DR
    Inflamm Bowel Dis; 2014 Dec; 20(12):2247-59. PubMed ID: 25358062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
    Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
    Kantasiripitak W; Outtier A; Wicha SG; Kensert A; Wang Z; Sabino J; Vermeire S; Thomas D; Ferrante M; Dreesen E
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1045-1059. PubMed ID: 35706358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.